| 摘要 |
A process for the preparation of a therapeutic agent from tumor cells for the therapy of tumorous diseases is described. This entails either human tumor cells which carry antigens which are bound by the monoclonal antibodies which recognize an antigen (Ag1) having a molecular weight of approximately 33 KD + 3, or an antigen (Ag2) having a molecular weight of approximately 134 KD + 3, or an antigen (Ag3) having a molecular weight of approximately 80 KD + 3, or an antigen (Ag4) having a molecular weight of approximately 55 KD + 3, or an antigen (Ag5) having a molecular weight of approximately 60 KD + 3, or an antigen (Ag6) having a molecular weight of approximately 54 KD + 3, or an antigen (Ag7) having a molecular weight of approximately 260 KD + 3, or an antigen (Ag8) having a non-determinable molecular weight, or an antigen (Ag9) having a non-determinable molecular weight, or an antigen (Ag10) having a molecular weight of approximately 143 KD + 3 and 119 KD + 3, or an antigen (Ag11) having a molecular weight of approximately 178 KD + 3, or an antigen (Ag12) having a non-determinable molecular weight, or an antigen (Ag13) having a molecular weight of approximately 34 KD + 3, or an antigen (Ag14) having a molecular weight of approximately 195 KD + 3, or an antigen (Ag15) having a molecular weight of approximately 44 KD + 7, or an antigen (Ag16) having a molecular weight of approximately 43 KD + 3, or an antigen (Ag17) having a molecular weight of approximately 130 KD + 3, being dried or stabilized by chemical treatment, or antigens being isolated from human tumor cells using these monoclonal antibodies, and being processed to a therapeutic agent, neuraminidase being added where appropriate. |
